Publications by authors named "Peter Bojko"

Claim this Profile
M
Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML.
Julian Stein, Philipp Anand, Joudi Abdulmajid, Anne Hartz, Marianne Unterfrauner, Peter Bojko

Int J Mol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DC mediated T-cell activation and on-target/off-tumor toxicity.
Hazal Aslan Rejeski, Anne Hartz, Elias Rackl, Lin Li, Christoph Schwepcke, Peter Bojko

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo.
Elias Rackl, Anne Hartz, Hazal Aslan Rejeski, Lin Li, Lara Kristina Klauer, Peter Bojko

Mol Immunol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.
Olga Schutti, Lara Klauer, Tobias Baudrexler, Florian Burkert, Joerg Schmohl, Peter Bojko

Int J Mol Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.
Marianne Unterfrauner, Hazal Aslan Rejeski, Anne Hartz, Sophia Bohlscheid, Tobias Baudrexler, Peter Bojko

Int J Mol Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study.
Thomas Wimmer, Raphael Mattes, Hans-Joachim Stemmler, Fabian Hauck, Hendrik Schulze-Koops, Peter Bojko

Blood Adv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.
Elias Rackl, Lin Li, Lara Kristina Klauer, Selda Ugur, Elena Pepeldjiyska, Peter Bojko

Int J Mol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study.
Alexander Höllein, Peter Bojko, Sebastian Schulz, Julia Neitz, Oliver Stötzer

Acta Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients.
Jannik Stemler, Caroline Bruns, Sibylle C Mellinghoff, Nael Alakel, Hamdi Akan, Peter Bojko

J Fungi (Basel)· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consultation Program for Patients with Cancer-Related Fatigue: A Systematic Evaluation of the Experiences of the Bavarian Cancer Society.
Irene Fischer, Carola Riedner, Peter Bojko, Manfred E Heim, Jens U Rüffer

Oncol Res Treat· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metronomic oral cyclophosphamide in patients with advanced solid tumors.
Peter Bojko, Gudrun Schimmel, Daniel Bosse, Wolfgang Abenhardt

Onkologie· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
Peter Bojko, Wolfgang Abenhardt, Susanne Schnittger, Torsten Haferlach

Onkologie· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Susanne Schnittger, Ulrike Bacher, Claudia Haferlach, Dietrich Beelen, Peter Bojko

Haematologica· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of commercial CD34 control samples for quality assurance.
Peter Bojko, Werner Stellberg, Veit Mansmann, Siegfried Seeber

Clin Lab· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
Sebastian Bauer, Volker Hagen, Hermann J Pielken, Peter Bojko, Siegfried Seeber

Anticancer Drugs· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis